J. Klijn

发表

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

Nazneen Rahman, Michael Bremer, Julian Peto, 2004, American journal of human genetics.

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer

C. Seynaeve, J. Klijn, E. Meijers-Heijboer, 2000, British Journal of Cancer.

Presymptomatic testing for BRCA1 andBRCA2: how distressing are the pre-test weeks?

P. Devilee, A. Wagner, H. Duivenvoorden, 1999, Journal of medical genetics.

Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.

P. Devilee, A. Wagner, H. Duivenvoorden, 1999, Journal of medical genetics.

Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.

C. Seynaeve, A. Eggermont, J. Klijn, 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to egf receptors

J. Foekens, J. Klijn, J. Laissue, 1990, International journal of cancer.

The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study.

J. Foekens, J. Klijn, E. Berns, 1993, European journal of cancer.

MRI screening for breast cancer in women with high familial and genetic risk: First results of the Dutch MRI screening study (MRISC).

R. Tollenaar, C. Boetes, M. Kriege, 2003 .

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

J. C. Houwelingen, L. J. Veer, S. Verhoef, 2005, Journal of Medical Genetics.

Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for theBRCA1/BRCA2 gene mutation in The Netherlands

J. Klijn, M. Niermeijer, R. W. Trijsburg, 2000, Journal of medical genetics.

BRCA1 in the family: a case description of the psychological implications.

P. Devilee, J. Oosterwijk, A. Tibben, 1997, American journal of medical genetics.

Prognostic factors and response to therapy in breast cancer.

J. Foekens, E. Berns, J. Klijn, 1993, Cancer surveys.

Novel endocrine therapies in breast cancer.

J. Foekens, C. Seynaeve, M. Bontenbal, 1996, Acta oncologica.

Should prophylactic surgery be used in women with a high risk of breast cancer?

N. Janin, R. Colomer, J. Klijn, 1997, European journal of cancer.

Genetic testing in hereditary non-polyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation

H. Meijers-Heijboer, A. Wagner, H. Vasen, 2002, Journal of medical genetics.

Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group.

R. Paridaens, R. Sylvester, J. Julien, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LH-RH agonists in the treatment of metastatic breast cancer: ten years' experience.

J. Klijn, 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

M. Stratton, M. J. van de Vijver, J. Chang-Claude, 1998, Journal of the National Cancer Institute.

Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling.

H Clevers, M van de Wetering, N Barker, 2001, Cancer research.

Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881

M. Piccart, L. Mauriac, J. Jassem, 1998 .

Growth Factors

J. Foekens, M. Bontenbal, J. Klijn, 1993, Annals of the New York Academy of Sciences.

Critical review of growth factors as clinical tools in primary and metastatic breast cancer.

J. Foekens, W. van Putten, J. Alexieva-Figusch, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Effect on a Dutch family of predictive DNA-testing for hereditary breast and ovarian cancer

P. Devilee, A. Tibben, J. Klijn, 1994, The Lancet.

The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

J G Klijn, J. Foekens, J. Klijn, 1992, Endocrine reviews.

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

J. C. Houwelingen, L. J. Veer, S. Verhoef, 2005, Journal of Medical Genetics.

Psychological impact of receiving a BRCA1/BRCA2 test result.

J. Klijn, A. V. D. van den Ouweland, A. Wagner, 2001, American journal of medical genetics.

Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation

P. Devilee, C. Seynaeve, A. Wagner, 2000, The Lancet.

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

J. Klijn, P. Devilee, A. Ouweland, 1998, The Lancet.

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant

M. Schutte, R. Tollenaar, P. Devilee, 2004, Journal of Medical Genetics.

Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.

E. Berns, C. Seynaeve, C. Brekelmans, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer

P. Devilee, H. Meijers-Heijboer, D. Ford, 1995, Human Genetics.

The prognostic value of plasminogen-activator inhibitor-1 (PAI-1) and the metastasis-associated proteases urokinase (uPA) and cathepsin-D in primary breast cancer: A multivariate analysis in 657 patients

J. Foekens, F. Jänicke, M. Schmitt, 1993 .

Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.

J. Foekens, B. Thirion, H. Portengen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Scientific background of hormonal treatment of prostate cancer.

J. Klijn, 1990, Progress in clinical and biological research.

Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study

J. Foekens, S. Henzen‐Logmans, J. Klijn, 1992, Journal of Cancer Research and Clinical Oncology.

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.

J. Klijn, M. Piccart, L. Mauriac, 2000, Journal of the National Cancer Institute.

PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

J. Foekens, M. Bontenbal, J. Klijn, 2006 .

Pre-clinical and clinical treatment of breast cancer with antiprogestins.

J. Foekens, S. Lamberts, F. de Jong, 1994, Human reproduction.

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

R. Blamey, R. Blamey, R. Sylvester, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Laser microdissection and microarray analysis of breast tumors reveal ER-α related genes and pathways

J. Foekens, A. Sieuwerts, M. Timmermans, 2006, Oncogene.

The prognostic value of epidermal growth factor receptors determined both by immunohistochemistry and ligand binding assay, in primary epithelial ovarian cancer (OC)

J. Foekens, S. Henzen‐Logmans, W. V. Putten, 1993 .

Short‐term versus long‐term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer

J. Klijn, R. Sylvester, U. Studer, 1993, Cancer.

Advanced breast cancer and its prevention by screening.

H. D. de Koning, J. de Haes, P. J. van der Maas, 1992, British Journal of Cancer.

Impact of screening for breast cancer in high-risk women on health-related quality of life

H. D. de Koning, M. Essink‐bot, G. Borsboom, 2004, British Journal of Cancer.

Abstract P4-07-01: Correlation of Breast Cancer Susceptibility Loci with Patient Characteristics, Metastasis-Free Survival and Expression of the Nearest Genes

A. Uitterlinden, S. Sleijfer, J. Foekens, 2010 .

Possible consequences of applying guidelines to healthy women with a family history of breast cancer

W. E. Hoogendoorn, R. Tollenaar, P. Devilee, 2003, European Journal of Human Genetics.

Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study

J. Klijn, H. Meijers-Heijboer, C. Seynaeve, 2006, Clinical genetics.

A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT)

R. Sylvester, W. Jonat, L. Mauriac, 1998 .

Gene expression profiles and molecular classification to predict distant metastasis and tamoxifen-resistant breast cancer

J. Martens, D. Atkins, E. Berns, 2005, Breast Cancer Research.

Allelotype of 28 human breast cancer cell lines and xenografts

M. Schutte, W. Dinjens, E. Berns, 2003, British Journal of Cancer.

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2

P. Devilee, H. Meijers-Heijboer, N. Hoogerbrugge, 2005, Breast Cancer Research.

LHRH-agonist versus chemotherapy in premenopausal breast cancer?

J. Klijn, 2002, European Journal of Cancer.

Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.

M. Schutte, R. Tollenaar, P. Devilee, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.

R. Paridaens, R. Sylvester, J. Jassem, 1998, British Journal of Cancer.

[Prognostic factors in thyroid carcinoma: follow-up findings in 429 patients].

W. van Putten, J. Alexieva-Figusch, J. Klijn, 1986, Nederlandsch tijdschrift voor geneeskunde.

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

J. Foekens, J. Klijn, M. Look, 2001, British Journal of Cancer.

Survival in hereditary breast cancer associated with germline mutations of BRCA2.

J. Klijn, P. Devilee, C. Seynaeve, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.

J. Klijn, E. Berns, P. Devilee, 2001, European journal of cancer.

Passive coping and psychological distress in women adhering to regular breast cancer surveillance

H. Duivenvoorden, A. Tibben, J. Klijn, 2007, Psycho-oncology.

Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.

J. Foekens, J. Klijn, E. Berns, 1992, British Journal of Cancer.

Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.

J. Klijn, C. Seynaeve, A. V. D. van den Ouweland, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival and prognostic factors in BRCA1-associated breast cancer.

J. Klijn, H. Meijers-Heijboer, C. Seynaeve, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC)

C. Boetes, H. D. de Koning, J. Klijn, 2001, Familial Cancer.

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

J. Foekens, J. Klijn, B. Thirion, 1994, British Journal of Cancer.

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.

J. Foekens, J. Klijn, K. Wingerden, 1997, British Journal of Cancer.

Presymptomatic testing for BRCA 1 and BRCA 2 : how distressing are the pre-test weeks ?

P. Devilee, A. Wagner, C. Cornelisse, 1999 .

Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing.

J. Klijn, H. Meijers-Heijboer, C. Seynaeve, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of the Rotterdam study on prophylactic mastectomy versus surveillance in BRCA1/2 mutation carriers.

H. Meijers-Heijboer, C. Seynaeve, M. Menke-Pluymers, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.